Introduction {#s1}
============

Idiopathic normal pressure hydrocephalus (iNPH) is the only variant of dementia disorders possibly treatable by neurosurgical intervention. iNPH is a neurodegenerative condition clinically characterised by gait ataxia, urinary incontinence and memory disturbance (the so-called Hakim\'s triad).[@R1]

In contrast with other types of dementia, ataxia represents an early and possibly pathognomic sign of iNPH. Neuroimaging typically shows dilated ventricles in the absence of increased intracranial pressure. Current pathophysiological models attribute iNPH to a complex dysfunction of cerebral blood flow with accompanying changes in CSF physiology rather than a simple imbalance of liquor production and resorption.[@R2]

The precise epidemiology of iNPH in industrialised countries remains to be defined. Data from Norway suggest an overall 5 year incidence of 1.1/100 000, which may increase to 30.2/100 000 in subjects over 65 years of age.[@R3]

Ventriculoperitoneal (VP) shunt surgery is a widely established intervention for iNPH although there is no conclusive evidence from controlled trials demonstrating superior outcomes of VP shunting over possible alternative treatment options (eg, endoscopic third ventriculostomy (ETV), or even watchful waiting).[@R4] [@R5] In the Hydrocephalus Association Survey 2003--2005, patients who underwent surgery had a non-significant reduction in the relative risk (RR) of dependent living compared with non-operative management (14/185 vs 6/66, RR 0.83, 95% CI 0.33 to 2.08). While more shunt patients reported improved health related quality of life, they required heightened care compared with endoscopic third ventriculostomy patients.[@R6]

VP shunting carries the risk of overdrainage complications, such as hygroma and subdural bleeding, which may cause severe headaches and nausea, subsequently demanding revision surgery.

The only current randomised trial on this condition, the Dutch Hydrocephalus Study, showed that low pressure valves lead to better neurological outcomes than medium pressure valves but are associated with a 3.3 (95% CI 1.6 to 6.9) times higher RR of chronic subdural effusions.[@R7]

The key problem of all drainage concepts is the posture dependent hydrostatic pressure change in a VP shunt. If the valve is programmed to provide adequate intraventricular and shunt pressure with the patient in the supine position, it may rapidly change to overdrainage in the upright position. If the valve pressure is set too low with the patient standing, underdrainage may occur in the horizontal position, compromising the beneficial effect of shunt surgery.

Recently, gravitational ball-in-cone units have been developed to overcome this siphoning effect by switching between a low pressure mode in the supine position and a high pressure mode in the upright position.[@R8; @R9; @R10]

Although plausible, it is unclear whether the more expensive gravitational valves improve the risk--benefit ratio of shunt surgery in iNPH patients.

We hypothesised that gravitational devices reduce the risk of overdrainage complications while, at the same time, they maintain the efficacy of conventional valves. To prove this hypothesis, we conducted a multicentre randomised trial of VP shunting with either a gravitational or a non-gravitational valve in patients with iNPH.

Methods {#s2}
=======

General remarks {#s2a}
---------------

The SVASONA (Shunt Valves plus shunt Assistant versus Shunt valves alone for controlling Overdrainage in idiopathic Normal pressure hydrocephalus in Adults) study was a pragmatic, multicentre, open label, randomised, parallel group trial conducted at seven centres in Germany. The trial investigated two different concepts of surgical CSF drainage in iNPH---that is, posture adapted CSF drainage using a gravitational unit versus shunting by a programmable valve. The primary objective of the study was to assess whether gravitational valve shunts can significantly reduce overdrainage complications compared with programmable valves, thereby improving the therapeutic index of shunt surgery for iNPH. Secondary objectives were to evaluate neurological recovery and the health related quality of life of patients undergoing either procedure.

In the planning phase of the trial, we searched PubMed Medline, Embase and the Cochrane Library with the terms 'normal pressure hydrocephalus', 'shunt\*', 'surg\*', 'valve\*' and 'outcome\*' for randomised trials as well as systematic reviews, for any available evidence to answer our research question. We also reviewed the databases of clinicaltrials.gov and Current Controlled Trials (ISRCTN) for ongoing studies on the topic.

We could not identify any other published or currently recruiting trial comparing standard programmable and gravitational valves in a head to head fashion for the surgical treatment of the disease of interest. This lack of evidence from randomised controlled trials supported the need for this trial, and stressed that the equipoise principle was met.

Participants {#s2b}
------------

We enrolled consecutive patients who gradually developed gait disturbance unexplainable by other health conditions, and showed at least one other clinical sign of the Hakim\'s triad suggesting the presence of iNPH (dementia and incontinence).[@R11]

Eligible patients had to demonstrate a communicating hydrocephalus with enlarged lateral ventricles, equalling an Evans Index of 0.3 or higher, as verified by CT or MRI.[@R12] The Evans Index is defined as the maximum frontal horn ventricular width divided by the transverse inner diameter of the skull in the same slice. A ratio of 0.3 or higher represents the classic threshold for diagnosing ventriculomegaly.

Also, at least one positive result out of the following pattern of invasive tests was required for patient inclusion: (1) resistance to outflow (R~out~) of 13 mm Hg/min×ml or more in the lumbar CSF infusion test,[@R13; @R14; @R15; @R16; @R17; @R18] (2) clinical improvement after a lumbar spinal tap or (3) positive B wave analysis.[@R17] [@R19; @R20; @R21; @R22]

We excluded patients with secondary NPH due to bleeding or infection, cerebral parenchymal lesions on CT or MRI scans, or any contraindication for surgery. Patients were also excluded if, according to the screening physician\'s judgment, they were unlikely to attend the planned follow-up visits. This included long distance travel, impaired mobility, low compliance or a presumed limited remaining lifespan.

The trial protocol was approved by the institutional review boards of the coordinating centre (Charité Medical University Centre, Berlin, Germany, EA1/165/06) and all collaborating institutions. The study was conducted in accordance with Good Clinical Practice and federal medical device regulations. All devices employed in the study were approved for clinical use under European laws.

Randomisation {#s2c}
-------------

After obtaining written informed consent from patients or their closest relatives, participants were randomised in a 1:1 fashion to either treatment group using a block randomisation plan (using the <http://www.randomization.com> online random sequence generator). Computer generated random lists and sealed envelopes were prepared by the central statistical unit and distributed to the collaborating institutions. For practical reasons and because of varying access to high speed internet connections in the operating theatres of the collaborating centres, we preferred the envelope approach over a web based randomisation tool. Sealed envelopes were opened immediately before surgery in the operating theatre. A treatment allocation sheet signed by a surgeon was faxed to the coordinating site to ensure that treatment assignment at individual centres matched the original randomisation sequence.

Procedures {#s2d}
----------

All patients underwent implantation of a silicone VP shunt under general anaesthesia carried out by experienced surgeons accredited for the study, using programmable units with similar hydrodynamic characteristics.[@R23] [@R24] Participants were randomly assigned to receive either a gravitational device (proGAV, Aesculap-Miethke, Potsdam, Germany) or a programmable valve (CMPV, Codman and Shurtleff, Johnson and Johnson, Ryanham, Massachusetts, USA).

Valves were implanted with an opening pressure of 100 mm H~2~O. Three months after surgery they were adjusted to the low pressure range (70 mm H~2~O). This was done because the Dutch iNPH study suggested better outcomes in patients with low pressure valves compared with medium high pressure valves. The decision about opening pressure thresholds of gravitational units was taken at the discretion of the collaborating centres. Manufacturers' recommendations were adhered to throughout the process.

Trial specific visits and data collection were scheduled at baseline, discharge, and after 6 and 12 months of follow-up. Available resources for this trial prohibited a tighter follow-up scheme, as well as an expansion of the observation period. All patients underwent a baseline cranial CT as well as the required CT scan 6 months after randomisation. Additional CT or MRI scans were ordered at the discretion of local investigators.

Changes in neurological status were assessed with two disease specific outcome tools[@R25]: the Black Grading Scale and the Kiefer Score.

The 6 point Black Scale introduced in 1980 classifies outcomes as excellent (resumed pre-illness activity without deficit), good (resumed pre-illness activity with moderate deficit), fair (improved, but no return to previous work), transient (temporary major improvement), poor (no change or worse) and dead (deceased within 6 weeks after surgery or as a result of surgery).

The Kiefer Score attempts to grade the severity of the three key symptoms of iNPH (mental deficits, gait disturbance, incontinence) and two additional minor symptoms (headache and dizziness).[@R26] The overall score may reach values between 0 and 24, with higher scores indicating more severe impairment.[@R27]

We also evaluated health related quality of life with the generic Short Form 12 V2.0 (SF-12) questionnaire, calculating population norm based Physical (PCS) and Mental (MCS) Component Scores.

The central coordinating unit prepared electronic case report forms (CRF) run on study specific laptop computers at the different trial sites. Two research assistants were responsible for telephone and on site monitoring of data during the study and after database closure.

The primary trial endpoint was any overdrainage complication occurring within 6 months after randomisation, as determined by local investigators. The diagnosis of overdrainage was verified by two neurosurgeons at the coordinating centre based on a consensus review of CRF entries and CT reports. Overdrainage was defined as any clinical symptom suggestive of overdrainage (headache, nausea, vomiting) requiring readjustment of the valve to a pressure of 90 mm H~2~O or more, the presence of subdural hygroma or haematoma with a thickness of at least 3 mm, a slit ventricle in CT scans or subsequent crossover from the programmable to the gravitational device.

Categorical secondary endpoints were surgical revision resulting from any cause, surgical site infections, ventriculitis and underdrainage. The latter was defined as ongoing ventricle enlargement accompanied by a secondary increase in symptoms.

Ordinal and continuous secondary endpoints included raw values and longitudinal changes in Black Scales, Kiefer Scores, SF-12 PCS and MCS, and the Evans Index.

The SVASONA trial compared approved and established devices. Adverse events and serious adverse events were recorded cumulatively and evaluated for their association with the procedure and devices under investigation by a panel of investigators at regular study meetings.

Statistical analysis {#s2e}
--------------------

All endpoints were analysed on an intention to treat basis. Only intention to treat results are presented here.

In the Dutch Normal Pressure Hydrocephalus Study, the incidence of all subdural effusions was 51/96, with 31 effusions being permanent (32%, 95% CI 23% to 46%).[@R7] A later case series showed a similar overall incidence of symptomatic overdrainage complications with the standard of care, the programmable Codman-Hakim valve, of 189/583 (32%, 95% CI 29% to 36%).[@R28] For this study, we assumed a control event rate of 25%. A risk reduction of 15% was considered realistic and clinically relevant by the panel of investigators. To demonstrate this difference with a power of 80% (plus a power reserve of 3%) and a two sided α error of 5%, 123 patients had to be evaluated in either group. As an early stopping rule, the trial would have had to be discontinued prematurely if the upper or lower z values for the difference in proportion exceeded 2.96 or −2.96, or the p value was lower than 0.0031 at the time of the interim analysis after inclusion of 50% of the target sample.

Results are presented as numbers, proportions, means and medians, according to the underlying distribution of the data. Differences between groups are expressed as risk differences, risk ratios (RR) and mean differences. Estimates of precision include ranges, interquartile ranges, SDs and 95% CI.

For confirmatory analysis of the primary endpoint, we used a generalised linear model to assess differences in proportions with a binomial variance and the logit link function. This model was also used to determine differences in secondary binary endpoints and to adjust the estimates for centre effects and key demographic variables (age, sex, body mass index (BMI), the American Society of Anaesthesiologists physical status classification system (ASA) and the Charlson Comorbidity Index).

Longitudinal changes in radiological measures, and disease specific and generic quality of life assessment instruments were evaluated by analysis of variance. The STATA 11 statistical software package (StataCorp LP, College Station, Texas, USA) was used for all analyses.

Results {#s3}
=======

A total of 145 patients were enrolled in the study. Complete data were available for 137 participants at the 6 month follow-up date. The observed risk difference in overdrainage events exceeded the expected effect size (z=−4.1) and the statistical discontinuation limit. Consequently, the investigators decided to terminate the trial at this stage. One slow recruiting trial centre did not comply with the protocol and so five patients originally enrolled at this centre were excluded from further analysis ([figure 1](#JNNP2012303936F1){ref-type="fig"}).

![Trial profile and patient selection procedure according to CONSORT recommendations. ITT, intention to treat.](jnnp-2012-303936f01){#JNNP2012303936F1}

Eligible participants in the study (89 men and 56 women) had a mean age of 71.9 years (SD 6.9; range 44 to 83 years). Baseline demography was similar in the groups, except for a slightly higher number of men randomly assigned to the non-gravitational device group ([table 1](#JNNP2012303936TB1){ref-type="table"}).

###### 

Baseline characteristics of the patients included in the SVASONA trial

                                                       Programmable valve group (n=71)   Gravitational valve group (n=74)
  ---------------------------------------------------- --------------------------------- ----------------------------------
  Sex                                                                                    
   Male (n (%))                                        48 (68)                           41 (55)
   Female (n (%))                                      23 (32)                           33 (45)
  Age at surgery (years) (mean (SD))                   71.2 (7.0)                        72.7 (6.7)
  BMI (mean (SD))                                      28.6 (4.2)                        27.1 (4.1)
  Evans Index (mean (SD))                              0.38 (0.06)                       0.37 (0.05)
  Cortical atrophy, any grade (n (%))                  61 (86)                           67 (91)
  Mean intracranial pressure (mm H~2~O) (mean (SD))    9.6 (3.6)                         9.6 (3.1)
  ASA III patients (n (%))                             23 (32)                           25 (34)
  Charlson Comorbidity Index (n)                                                         
   Not indicated                                       8                                 7
   0                                                   18                                24
   1                                                   20                                20
   2                                                   9                                 11
   3                                                   7                                 7
   4                                                   7                                 5
   \>4                                                 2                                 0
  Duration of surgery (min) (mean (SD))                60.5 (22.5)                       61.9 (23.7)
  Duration of hospital stay (days) (mean (SD))         7.9 (4.3)                         7.1 (3.9)
  Gravitational unit opening pressure (mm H~2~O) (n)                                     
   200                                                                                   20
   250                                                                                   34
   300                                                                                   16
   350                                                                                   4
  Postoperative CT scan (n (%))                        70 (99)                           71 (96)
  Interval to postoperative CT (days) (mean (SD))      3.9 (3.7)                         4.2 (4.5)

ASA, American Society of Anaesthesiologists physical status classification system; BMI, body mass index; SVASONA trial, Shunt Valves plus shunt Assistant versus Shunt valves alone for controlling Overdrainage in idiopathic Normal pressure hydrocephalus in Adults trial.

At the 6 month follow-up visit, 26 patients in the programmable valve group and four patients in the gravitational shunt group showed signs and symptoms of overdrainage (risk difference −33%, 95% CI −46% to −20%; p\<0.001). Up until then, 16 patients (23%, 95% CI 13% to 34%) had already been or were scheduled to be implanted with a gravitational device. The cumulative incidence of overdrainage events, recorded from the index procedure to the trial visit 6 months after randomisation, was 29 and five, respectively (risk difference −36%, −49 to −23%; p\<0.001). Trial centre allocation, male sex, age, ASA class, Evans Index, Charlson comorbidity severity, cortical atrophy grade, intracranial pressure or duration of surgery did not influence outcomes by themselves, as evaluated by general linear models.

The advantage of the gravitational valve over the programmable valve in reducing overdrainage held up until the 12 month follow up ([table 2](#JNNP2012303936TB2){ref-type="table"}). Two patients in the experimental trial arm died for reasons unrelated to the intervention.

###### 

Outcome by endpoint

  Assessment                               Valve   Risk difference (95% CI)   OR (95% CI)\*         p Value                
  ---------------------------------------- ------- -------------------------- --------------------- ---------------------- ----------
  Hospital stay (t1)                                                                                                       
   Participants                            71      74                                                                      
   Subdural effusion                       10      1                          −13% (−21% to −4%)    0.08 (0.01 to 0.67)    0.020
   Bleeding complications                  4       1                          −4% (−10% to 2%)      0.23 (0.03 to 2.10)    0.193
   Misplacement                            6       4                          −3% (−11% to 5%)      0.62 (0.17 to 2.29)    0.473
  Follow-up at 6 months (t2)                                                                                               
   Participants                            67      70                                                                      
   Subdural effusion                       24      4                          −30% (−43% to −17%)   0.11 (0.04 to 0.33)    \< 0.001
   Overdrainage                            26      4                          −33% (−46% to −20%)   0.10 (0.03 to 0.29)    \< 0.001
   Cumulative incidence of overdrainage    29      5                          −36% (−49% to −23%)   0.10 (0.04 to 0.28)    \< 0.001
   Underdrainage                           3       2                          −2% (−8% to 5%)       0.62 (0.10 to 3.82)    0.604
  Follow-up at 12 months (t3)                                                                                              
   Participants                            58      60                                                                      
   Subdural effusion                       12      0                          −21% (−31% to −10%)   --                     
   Overdrainage                            14      2                          −21% (−33% to −9%)    0.10 (0.02 to 0.46)    0.003
   Cumulative incidence of overdrainage    34      7                          −44% (−59% to −30%)   0.10 (0.04 to 0·24)    \<0.001
   Underdrainage                           8       1                          −12% (−21% to −3%)    0.00 (0.01 to 0.84)    0.033
  Cumulative incidence of adverse events                                                                                   
   Wound infection                         1       2                          1% (−3% to 6%)        1.94 (0.17 to 21.93)   0.591
   Local bleeding                          4       1                          −4% (−10% to 2%)      0.23 (0.03 to 2.10)    0.193
   Malplacement                            6       4                          −3% (−11% to 5%)      0.62 (0.17 to 2.29)    0.473
   Device exchange                         3       1                          −3% (−8% to 2%)       0.31 (0.03 to 3.06)    0.316
   Pressure adjustment                     29      28                         −3% (−19% to 13%)     0.88 (0.45 to 1.72)    0.711
   Death                                   0       2                          3% (−1% to 6%)        --                     

\*Derived from generalised linear model, unadjusted data.

Overall, the incidence of adverse events was low. No supposed unexpected serious adverse reactions, in particular no device related adverse events, were observed during the trial period.

The morphological indicator of ventricle enlargement, the Evans Index, decreased over time (p=0.001) but was unrelated to the treatment group (p=0.537) ([figure 2](#JNNP2012303936F2){ref-type="fig"}). The disease specific Black Scale did not change between the 6 and 12 month assessments (mean difference 0.15, 95% CI −0.06 to 0.36). In contrast, the Kiefer Scale decreased after shunting (p\<0.001) without showing a significant difference between treatment groups (p=0.339) ([figure 3](#JNNP2012303936F3){ref-type="fig"}).

![Longitudinal changes in ventricular enlargement, as indicated by the Evans Index.](jnnp-2012-303936f02){#JNNP2012303936F2}

![Disease specific outcomes by time and treatment group measured by the Kiefer Scale.](jnnp-2012-303936f03){#JNNP2012303936F3}

SF-12 PCS improved over time, again without a difference between implant type. It is of note that MCS showed better ratings (p\<0.001) in the gravitational group after 6 months ([figure 4](#JNNP2012303936F4){ref-type="fig"}).

![Generic health outcomes as assessed by the Short Form 12 (SF-12) and its physical (PCS) and mental (MCS) Component Scores.](jnnp-2012-303936f04){#JNNP2012303936F4}

Discussion {#s4}
==========

The key finding of this multicentre trial is that, if shunt surgery is considered the treatment option of choice for patients with confirmed iNPH, it should be performed using a gravitational valve. The latter may prevent one additional overdrainage complication in every third patient undergoing shunting with a gravitational compared with a non-gravitational programmable valve.

This assumption is mainly supported by surrogate measures (ie, overdrainage complications) although our results also suggest an advantage of gravitational valves over other programmable valves in the mental domains of health related quality of life.

While the observed point estimate of overdrainage incidence in the control group increased compared with previous reports by about 10%,[@R7] 95% CI of proportions still overlapped. Thus there is currently no divergence of the present from the available body of evidence.

The present data may not help neurosurgeons in counselling patients and their relatives to opt for or against a surgical intervention. However, they may guide healthcare professionals in choosing the most appropriate device to avoid secondary interventions. The additional costs of gravitational units are likely to be offset by savings in later care, although this assumption needs to be confirmed by health economy studies, formally investigating the incremental cost effectiveness ratio and the dominant treatment strategy.

Pragmatic trial designs, as chosen for this investigation, are intended to ease implementation of protocol driven procedures and assessments, enhance recruitment rates and increase external validity of results. This comes at the price of a less stringent definition of exposure and outcome variables, introducing some heterogeneity.

For example, the need for pressure adjustment, valve exchange or replacement of a programmable valve by a shunt assistant valve was performed at the discretion of local investigators (although verified by a review of CRFs and CT reports).

In the Dutch iNPH trial, eight of 51 (16%) subdural effusions demanded therapeutic action. Patient centred outcomes, as assessed by the customised NPH Scale Score, did not differ between patients with and without bleedings or hygromas. The surgical revision rate for intracranial complications in this study 6 months after randomisation was similar (five of 28, or 18%).

Imaging findings alone may have a low specificity, introducing non-differential misclassification of outcomes and bias towards the null.[@R29]

Subdural effusions may also represent residual intraoperative bleedings rather than a surrogate of overdrainage. Due to our pragmatic trial design, we mainly relied on the interpretation of primary and follow-up CT scans by neurosurgeons and radiologists at participating units.

A secondary analysis of our data showed that gravitational valves significantly reduced the RR of overdrainage symptoms (ie, headache, nausea and vomiting) by 62% (RR 0.38, 95% CI 0.14 to 1.00). The RR of symptomatic subdural effusions was reduced by 90% (RR 0.10, 95% CI 0.01 to 0.75) 6 months after randomisation. Thus, apart from some imprecision inherent in the primary composite endpoint, the beneficial effect of gravitational valves was sustainable from a clinical and patient centred perspective.

There is currently no generally accepted or formally validated outcome measure for iNPH.[@R25] This study was conducted at German centres, and we wanted to guarantee that local investigators were familiar with the assessment instruments. The Kiefer Scale is a nationally established and accepted tool. Yet, unless translated, re-translated and evaluated with regard to its psychometric properties, our data may lack some external validity. To overcome this possible shortcoming, we added another disease specific tool (ie, the Black Scale), that was used in several case series published in the 1980s, to give us some idea of the grade of neurological improvement and recovery after shunting.[@R30; @R31; @R32]

Future trials may include neuropsychological tests to record patient outcomes. For example, the recent European Multicenter Study on iNPH employed the Grooved Pegboard, Stroop Test and Auditory Verbal Learning Test to monitor treatment effects after shunting.[@R33]

Assessment of the three key domains of health related quality of life (ie, physical, mental, social) in patients with dementia is challenging, and common generic instruments such as the Short Form family (ie, SF-36, SF-12, SF-8) or the Euro-Quality of Life 5D (EQ-5D) may fail in this setting.[@R34] Differences in the reliability (or internal consistency, the ability of an instrument to measure something the same way twice) between the eight domains of the SF36 have been observed among elderly patients with (Mini-Mental State Examination score≤23) and without (Mini-Mental State Examination score \>24) cognitive impairment.[@R35] The advantage of the SF-12 used in the SVASONA trial is its simplicity, and the availability of normalised PCS  and MCS. The values allow for a basic comparison of the health status of the study sample to a gender and age matched norm population. Altogether, the observed trends in Kiefer, Black and SF-12 PCS give confidence that neurological outcomes between the valve types under investigation are comparable.

The observation of normalisation of SF-12 MCS in the gravitational valve group, and consistently higher ratings compared with the programmable valve 6 and 12 months after randomisation, were unexpected. Effect sizes d (ie, mean differences divided by the pooled SD) were moderate (*d*=0.62 and *d*=0.31, respectively). These findings must, however, be interpreted with caution, given that the SF-12 is currently not validated in patients with iNPH and other types of dementia.

Further limitations of this study merit discussion. First, despite its multicentre design, the results may not be applicable to centres outside Europe. Regression analysis did not reveal differences between participating units with regard to the primary trial endpoint. However, we cannot exclude residual selection bias and centre effects because of the small sample size and premature discontinuation of patient enrolment. Second, we had to withdraw one centre from the study because of protocol violations, as revealed by rigorous monitoring. Although this deviation only affected five patients, it may have also resulted in selection bias. Third, a higher number of male patients were randomly assigned to the experimental group. Exploratory regression analysis did not indicate a significant impact of gender on primary trial outcomes. However, this imbalance may point to residual bias not eliminated by randomisation. Fourth, the available resources precluded more frequent and longer longitudinal assessments (eg, after 3 months and beyond 1 year). Thus we cannot make any statements about the subsequent risk of underdrainage in the gravitational trial arm after database closure. However, our data collected up to 1 year after randomisation did not suggest a higher, but rather a lower, rate of underdrainage with gravitational valves. Further studies are needed to investigate whether potential short term and mid term benefits of gravitational valves are offset by a higher risk of underdrainage in the long term.

A more technical issue of concern may be the chosen valve setting. The Dutch NPH study, our intellectual starting point prompting the SVASONA trial, clearly demonstrated that low pressure valves (set at 40 mm H~2~O) lead to significantly better outcomes than medium high pressure valves. Consequently, we aimed for a trial design with a general low pressure setting. On the other hand, it was obvious that the implantation of 50 mm H~2~O valves with and without a gravitational unit would cause hazardous overdrainage situations in many patients in the treatment arm without gravitational units. Thus we allowed for a slow adaptation from a high to a low pressure range, initially implanting both valves with 100 mm H~2~O and later adjusting them to 70 mm H~2~O after 3 months. We admit that this scheme is a compromise but it is still in accordance with manufacturers' recommendations and clinical practice.

Choosing the appropriate opening pressure of the gravitational unit remains a critical treatment step which was set according to the patient\'s body mass index. The rationale behind this is that the level of compensation for hydrostatic pressure changes ultimately depends on the height of the upper body and peritoneal pressure. However, only the hydrostatic difference between the upright and recumbent position can accurately be calculated. One may speculate whether overdrainage rates with gravitational units can further be lowered if it were possible to exactly determine the required degree of hydrostatic compensation.

In summary, gravitational valves showed a significant reduction in the incidence of surrogate markers of overdrainage up to 1 year following shunt surgery. While maintaining therapeutic efficacy and effectiveness (measured by disease specific outcome instruments such as the Black and Kiefer Scale), gravitational valves may have a superior therapeutic index compared with non-gravitational programmable valves. Possible advantages for mental components of health related quality of life demand further investigation. Health economy studies are ultimately needed to define the dominant treatment strategy, and to determine the most cost effective standard of care in patients with iNPH.
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